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Objectives: Seven cases of malignant lymphohematopoietic (LHP) disorder were claimed to have developed from occupational 
exposure at two plants of a semiconductor company from 2007 to 2010. This study evaluated the possibility of exposure to carci-
nogenic agents for the cases. 
Methods: Clinical courses were reviewed with assessing possible exposure to carcinogenic agents related to LHP cancers. Chemi-
cals used at six major semiconductor companies in Korea were reviewed. Airborne monitoring for chemicals, including benzene, 
was conducted and the ionizing radiation dose was measured from 2008 to 2010. 
Results: The latency of seven cases (five leukemiae, a Non-Hodgkin’s lymphoma, and an aplastic anemia) ranged from 16 months 
to 15 years and 5 months. Most chemical measurements were at levels of less than 10% of the Korean Occupational Exposure 
Limit value. No carcinogens related to LHP cancers were used or detected. Complete-shielded radiation-generating devices were 
used, but the ionizing radiation doses were 0.20-0.22 uSv/hr (background level: 0.21 μSv/hr). Airborne benzene was detected at 
0.31 ppb when the detection limit was lowered as low as possible. Ethylene oxide and formaldehyde were not found in the cases’ 
processes, while these two were determined to be among the 263 chemicals in the list that was used at the six semiconductor 
companies at levels lower than 0.1%. Exposures occurring before 2002 could not be assessed because of the lack of information. 
Conclusion: Considering the possibility of exposure to carcinogenic agents, we could not find any convincing evidence for oc-
cupational exposure in all investigated cases. However, further study is needed because the semiconductor industry is a newly 
developing one.
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Introduction
There have been several reports of  cancer outbreaks in semi-
conductor companies, such as IBM in the United States [1,2] 
and the National Semiconductor UK (NSUK) in the United 
Kingdom [3,4]. Recently, the Health and Safety Executive 
(HSE) of the UK announced that there was no evidence link-
ing working at NSUK and cancer development [5]. However, 
there is still some debate on this matter [6].
From 2007 to 2010, the Occupational Safety and Health 
Research Institute (OSHRI) of the Korea Occupational Safety 
and Health Agency (KOSHA) investigated seven cases of 
malignant lymphohematopoietic (LHP) disorders, such as leu-
kemia, malignant lymphoma, and aplastic anemia, in a semi-
conductor company (Table 1) to evaluate work-relatedness, as 
requested by the Korea Workers’ Compensation & Welfare 
Service (COMWEL). OSHRI conducted an environmental 
assessment to find occupational carcinogens related with ma-
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lignant LHP disorder, focusing on benzene and ionizing radia-
tion in the victims’ workplaces. OSHRI also reviewed the seven 
patients’ medical records.
In 2008, OSHRI also conducted a retrospective cohort 
study in eight semiconductor factories to assess the mortal-
ity and incidence for LHP cancers of  Korean semiconductor 
workers. The results of  this cohort showed no significant in-
crease of leukemia. The standardized incidence ratio (SIR) of 
leukemia was 0.69 [95% confidence interval (CI): 0.30-1.37] in 
males and 1.28 (95% CI: 0.61-2.36, 10 cases) in females. How-
ever, non-Hodgkin’s lymphoma (NHL) in females was signifi-
cantly increased (2.31, 95% CI: 1.23-3.95) even though there 
was no definite association between work and those diseases 
in subgroup analysis according to work duration. The detailed 
result of this cohort study will be presented in another paper [7]. 
In the cohort study paper, the specific working environment 
and clinical course of the cases are not described. The purpose 
of this study is to provide details on the clinical course and the 
job exposures experienced by the seven LHP cases. 
Materials and Methods
From July 2007 to October 2010, OSHRI investigated seven 
cases of  malignant LHP disorder from two plants of  a semi-
conductor company in Korea. Three of  the subjects had 
worked in the wafer fabrication (FAB) department in Plant A, 
and the others were from the assembly (AS) departments in 
Plant B, which was located in a different city. Personal charac-
teristics and the clinical course, the manufacturing process of 
the plants, and the specific working environment and tasks of 
the cases were reviewed.
Results
Clinical characteristics and latency
The following cases were reviewed: four females with acute 
myeloid leukemia (AML) and a male with acute lymphoblastic 
leukemia (ALL, pre-B cell type), all 20-30 years old; a 38 year-
old male with NHL; and a 19 year-old female with aplastic 
anemia. Their working periods ranged from 1991 to 2007. The 
aplastic anemia case developed with the shortest latency (1 year 
and 4 months) of exposure. The longest latency was observed 
in the NHL case (15 years and 5 months) (Table 1). Two cases 
(Case No. 5 and 6) had been diagnosed 9-10 years after leaving 
the company.
All cases were non-smokers and all female workers had 
never drunk alcohol. The two male workers had drunk small 
amounts of  alcohol (about 6-12 ml for each worker) twice a 
month. No cases had a history of  habitual drug use. All the 
cases answered that none of their immediate family had been 
diagnosed with hematologic cancer or a related disorder.
Case No. 1
A 20-year-old (at the age of  diagnosis) female worker began 
working at a semiconductor company in October 2003 imme-
diately after she graduated high school. In 2004, she had a reg-
ular medical checkup, with normal findings for red blood cell 
counts (RBC), hemoglobin (Hb), hematocrit (HCT), and white 
blood cell counts (WBC). In May 2005, she visited a hospital 
due to various symptoms, such as bruising, vomiting, fatigue, 
and dizziness. She was subsequently diagnosed with leukemia 
in June 2005, which was classified as AML with granulocytic 
maturation (M2) by the French-American-British classification 
system. She received bone marrow transplantation in Decem-
Table 1. Latency and working period of the cases
Case No. Plant
Sex/age at 
diagnose
Diagnoses Working period
Date of 
diagnosis
Working duration Latency
1  A F/20 AML M2 OCT 2003-JUN 2005 JUL 2005 1 yr and 8 m 1 yr and 8 m
2 A F/30 AML M3 JAN 1995-JUL 2006 JUL 2006 11 yr and 3 m* 11 yr and 6 m
3  A M/29 ALL pre-B cell type NOV 1997-APR 2005 OCT 2004 7 yr and 5 m 6 yr and 11 m
4 B F/20 AML, M1 DEC 2004-SEP 2007 SEP 2007 2 yr and 9 m 2 yr and 9 m
5 B F/36 AML M3  JAN 1991-JAN 1996 MAY 2005 5 yr 14 yr and 4 m
6  B M/38 NHL, Diffuse large B Cell MAY 1993-DEC 1998 OCT 2008 5 yr and 7 m 15 yr and 5 m
7 B F/19 Aplastic anemia JUL 2000-NOV 2001 NOV 2001 1 yr and 4 m 1 yr and 4 m
AML: acute myeloid leukemia, ALL: acute lymphoblstic leukemia, NHL: non-Hodgkin’s lymphoma, yr: year, m: month.
*Except 3 months for the leave for child delivery.
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ber 2005; in November 2006, her clinical status aggravated and 
she died in March 2007 during re-remission treatment.
Case No. 2
A 30-year-old (at the age of  diagnosis) female worker began 
working in the semiconductor industry in January 1995. She 
visited outpatient clinics several times due to respiratory (acute 
and chronic laryngitis, allergic rhinitis, and chronic sinusitis) 
and dermatologic (xerodermia and allergic contact dermatitis) 
problems, and a miscarriage during 1998 to 2006. From 2003 
to 2005, the annual medical examination revealed that her 
RBC, WBC, and HCT were normal except for a mild decrease 
in Hb. In 2005, she became pregnant and gave a birth in April 
2006. She returned back to the work in June 2006. One month 
later after she returned to work, she visited a clinic due to pro-
ductive cough and gum bleeding, prompting a hospital visit in 
July 2006. She was then diagnosed with promyelocyte domi-
nant AML (M3, variant type by the FAB classification system) 
without abnormal chromosomal finding. She started remission 
chemotherapy right after diagnosis, but died in October 2006.
Case No. 3
A 29-year-old (at the age of  diagnosis) male worker began 
working in the semiconductor industry in November 1997. He 
had previously worked for two years in porcelain panel and 
clothes manufacturing companies where he packed cloths. 
Results of the periodic medical checkups were normal during 
2001 to 2004. His only previous health problem was contact 
dermatitis around the mouth due to wearing a mask at work. 
He was diagnosed with ALL (pre-B cell type) in October 2004. 
Before diagnosis, he had experienced a common cold, blood-
tinged sputum, and epistaxis for 3 weeks. After repeated remis-
sion and aggravation, he died in July 2007.
Case No. 4
A 20-year-old (at the age of  diagnosis) female worker began 
working in the semiconductor industry in December 2004. 
Routine blood tests in the pre-placement medical examination 
before entering the company and regular medical checkups in 
2005 and 2006 were normal. In May 2007, blood test results 
showed mild leukopenia (WBC count 3,180/mm3, Hb 10.2 g/
dL, and RBC count 321 × 104/mm3). She began to experience 
dyspnea, nausea, vomiting, and dizziness in August 2007, she 
visited a hospital in September 2007, and was then diagnosed 
with AML (M1, myeloblastic leukemia without maturation). 
The chromosomal study revealed deletion of  11q23 in Sep-
tember 2007, but was normal in repeated analysis in October 
2007. She received bone marrow transplantation in April 2008, 
but her condition aggravated the following month. She died in 
March 2010 after repeated chemotherapy. 
Case No. 5
A 36-year-old (at the age of  diagnosis) female worker began 
working in the semiconductor industry in January 1991 and 
quit in January 1996. In 2003, seven years after leaving the 
company, she felt severe fatigue and bruised frequently (no 
medical record existed before 2003, but she denied any health 
problems before then). She visited an outpatient clinic and was 
found to have mild leucopenia. She received a treatment for 
acute pyelonephritis in 2003 and 2004, and leucopenia was also 
found. In January 2005, she visited a hospital emergency room 
for high fever and pharyngitis and was found to have pancyto-
penia. After detailed tests, she was diagnosed with AML (M3) 
in May 2005. She started chemotherapy in March 2005 and 
was still undergoing treatment as of December 2010.
Case No. 6
A 38-year-old (at the age of  diagnosis) male worker with no 
remarkable past medical history began working in the semi-
conductor industry in May 1993 and left the company in De-
cember 1998 when he began working in real estate. Ten years 
later (October 2008), he felt an abnormal lump in his neck and 
enlargement of a lymphatic gland. He visited a hospital imme-
diately and was diagnosed with non-Hodgkin’s lymphoma of 
the diffuse large B cell type. His health checkup records during 
employment at Plant B could not be reviewed because these 
records are retained for only 3 years after employment termi-
nation, whereas this worker ceased employment at Plant B 10 
years before his lymphoma diagnosis. He is still being treated as 
of December 2010.
Case No. 7
A 19-year-old (at the age of  diagnosis) female worker began 
working in the semiconductor industry in July 2000. Routine 
blood tests in the periodic medical checkup found mild anemia 
(Hb 11.8 g/dL) in March 2001, and 8 months later (November 
2001) she visited a hospital due to subconjunctival hemorrhage, 
epistaxis, and vitreous hemorrhage. Bone marrow pathology 
revealed less than 5% cellularity and she was diagnosed with 
aplastic anemia. After the diagnosis was confirmed, she started 
chemotherapy; however, it did not work because of  repeated 
fever and her respiratory symptoms relapsed. She is currently 
waiting for bone marrow transplantation as of July 2010. 
Overview of Semiconductor manufacturing process
The semiconductor manufacturing process consists of  the 
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following three steps: production of  silicon wafers from very 
pure silicon ingots; fabrication of integrated circuits onto these 
wafers (FAB); assembly of every integrated circuit on the wafer 
into a finished product (AS) and testing of the finished prod-
ucts. The first step is purifying the silicon to make the raw ma-
terial for a chip. The chip is a semiconductor product through 
which ingot bare wafers are produced. The bare wafers, then, 
are transferred to the second step, where various chemicals are 
used to create circuits by adding and removing layers on the 
wafer. FAB processes are followed by assembly, testing, mark-
ing, packing, and shipping [8]. 
Major chemical and physical hazards in the semiconduc-
tor processes are shown in Table 2. There are several major 
process stages in FAB, such as diffusion, lithography, etching, 
ion implantation, deposition process, and polishing. In the dif-
fusion process, silicon dioxide (SiO2) is formed on a wafer using 
several gases. Before the oxidation, wafers should be cleaned 
thoroughly to remove particulates by using various kinds of ac-
ids and bases and isopropyl alcohol (IPA). Several different lay-
ers, each with a different pattern and all of which are required 
for circuits, are well defined by a process called lithography. 
Lithography uses a variety of solvent-based photoresists, devel-
opers, thinners, adhesion, and promoters. UV-light is used for 
exposure, from which secondary reactants can be generated. 
Etching removes deposited material on the wafer’s surface that 
is not covered by photoresists. Etching can be accomplished by 
a ‘wet’ processing using various acids and bases or a ‘dry’ pro-
cessing using gaseous species. In the ion implantation process, 
ion additives are shot into the wafer, creating the positively and 
negatively charged regions on the wafer. Arsine (AsH3), boron 
Table 2. Chemical and physical hazards of major semiconductor processes
Process Chemical Physical
Wafer fabrication Diffusion Cleaning  NH4OH, H2O2, HF, H2SO4, IPA 
  Oxidation NH3, BF3, SiH2Cl2, O2, N2, POCl3, SiH4
 Lithography Photoresists Resin: phenol or formaldehyde group resins UV light 
   Photosensitizer: DNQ, solvent: EB, 2HP, nBA, Xylene
  Adhesion promoter HMDS
  Developer Aliphatic hydrocarbon, TMAH
  Thinner Xylene, nBA, DMAc, EE, PGME, PGMEA 
 Etching Dry etching N2, He, O2, CF4, Cl2,CHF3, SF6, BCl3
  Wet etching Acetic acid, NH4F, NH4OH, HF, H2O2, Nitric acid, H3PO4, H2SO4, PG, OPE 
 Doping Ion implantation Ar, AsH3, BF3, PH3, HF, KOH X-ray
 Deposition CVD NF3, N2O, TEOS, HF, C3F8, PH3, NH3, SiH4, C3F8, B2H6
  Metallization Ar, Nitrogen, HF, NH4OH, H2O2, Tungsten
 Polishing CMP HF, HCl, HNO3, CeO2, NH4OH, KOH
Assembly Sawing, die attach,  No chemical 
   wire bond
 Mold, plating Lead, tin, bismuth
 Trim/form, sorter Trichloroethylene
 Testing  Quality engineering HCFC-141b, bismuth, lead, silver, copper, tin, isopropyl alcohol X-ray
CVD: chemical vapor deposition, CMP: chemical mechanical polishing, NH3: ammonia, BF3: borontrifluoride, SiH2Cl2: dichlorosilane, O2: Oxy-
gen, N2: Nitrogen , POCl3: phosphorus oxychloride, SiH4: silane, DNQ: diazonaphthoquinone, NH4OH: ammonium hydroxide, H2O2: hydrogen 
peroxide, HF: hydrofluoric acid, H2SO4: sulfuric acid, IPA: isopropyl alcohol, HMDS: hexamethyldisilazane, PGME: propylene glycol mono methyl 
ether, PGMEA: propylene glycol mono methyl ether acetate, DMAc: dimethylacetamide, EE: ethyl-3-ethyoxypropionate, EB: ethyl benzene, 
2HP: 2-hepatinone, nBA: n-buthyl acetate, TMHA: tetramethyl ammonium hydroxide, He: helium, CF4: carbon tetrafluoride, Cl2: chlorine, CHF3: 
trifluoro methane, SF6: sulfur hexafluoride, BCl3: boron trichloride, NH4F: ammonium fluoride, H3PO4: phosphoric acid, PG: polyethylene glycol, 
OPE: octylphenoxy-polyethylene ethanol, Ar: argon, AsH3: arsine, PH3: phosphine, KOH: potassium hydroxide, NF3: nitrogen trifluoride, N2O: 
nitrous oxide, TEOS: tetraethyl orthosilicate, SiH4: Silane, C3F8: Octafluoropropane, B2H6: diborane, HCFC-141b: 1,1-Dichloro-1-fluoroethane, 
HCl: hydrogen chloride, HNO3: nitric acid, CeO2: cerium oxide.
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trifluoride (BF3), and phosphine (PH3) are the most common 
chemicals used in this process. Because ion additives are in-
fused by an ion acceleration instrument, there might be a pos-
sible risk of  ionizing radiation exposure. Deposition refers to 
the deposition of additional material on the wafer surface and 
is composed of chemical vapor deposition (CVD) and metal-
lization. CVD uses diboran (B2H6), nitrogen trifluoride (NF3), 
nitrous oxide (N2O), silane (SiH4), and tetraethyl orthosilicate 
(TEOS). The most commonly used metals are aluminum, gold, 
nickel-chromium, and platinum, with copper being a recent 
addition. Polishing refers to planarization of the oxide layer of 
the wafer by chemical and physical means. A polishing fluid 
called slurry and several acids and bases are used. The third 
step involves putting the integrated circuit inside a package for 
shipping, and this process is known as semiconductor package 
assembly (AS). In general, AS consists of sawing off the wafer, 
attaching it to a support structure, bonding the wire, molding 
and plating, ‘trim and form’ and electrical testing. Most AS 
processes do not use chemicals. However, the molding and 
plating process may use resins or metals. Although the trim and 
form process does not use chemicals, solvents such as isopropyl 
alcohol are used for cleaning. During electrical testing, an X-
ray-generating instrument and various chemicals, such as iso-
propyl alcohol or 1,1-dichloro-1-fluoroethane, are used. After a 
lot is tested, it is taped and labeled for shipment.
Specific working environment and tasks 
Three of the investigated cases (two operators and an engineer) 
were from FAB in Plant A; the other four cases were from 
AS in Plant B. Plant A, founded in 1969, had approximately 
24,000 workers in 2008 and produced dynamic random access 
memory (DRAM), static random access memory (SRAM), 
and flash memory. Plant B, founded in 1991, had approximate-
ly 6,000 workers in 2008 and produced DRAM, SRAM, and 
liquid crystal display (LCD) modules. All clean room workers 
(AS or FAB workers) should wear a protective suit known as a 
‘bunny suit’ which is composed of all-in-one clothing, includ-
ing a mask, safety glasses, gloves, and boots. However, this suit 
is not chemically-resistant, and chemicals can soak through to 
the skin.
Table 3. Working process and task of the cases
Case 
No.
Depart Process Task
Working 
duration
Chemical exposure by the task Ionizing radiation
1 FAB (Plant A) Diffusion (L3 B1,22,24) Operator 14 m Remote exposure by ion implant
Wet etching (L3 B 3) 6 m H2O2, NH4F, HF, H2SO4
2 FAB (Plant A) Deposition (CVD) (L3 B 6, 9) Operator 9 yr 5 m Remote exposure by ion implant
Labeling (L3) 9 m
Wet etching (L3 B 3) 6 m H2O2, NH4F, HF, H2SO4
Diffusion (L3 B 22) 7 m
3* FAB (Plant A) CMP (Line 5, Bay 5) Process 4 yr 9 m Silica, NH4, IPA No exposure
Back-Lap (Line 1) Engineer 2 yr 8 m
4 AS (Plant B) QE lab Test 2 yr 9 m Tin, lead, Bismuth, HCFC-141b X-ray instrument of QE lab
5 AS (Plant B) Trim/Form Operator 5 yr TCE, HCFC-141b No exposure
6 AS (Plant B) Plating Process 
  engineer
5 yr 7 m Lead, tin, bismuth, KOH, H2SO4, 
H2O2, IPA, K2SO4, K2PO4,
CH3SO3H, Benzothiazole, HNO3
No exposure
7 AS (Plant B) MBT Test 1 yr 4 m VOCs from heating chamber No exposure
FAB: fabrication, AS: assembly, L: line, B: bay, CVD: chemical vapor deposition, CMP: chemical mechanical polishing, QE: quality engineering, 
MBT: monitoring burn-In test, m: month, yr: year, VOC: volatile organic compounds, H2O2: hydrogen peroxide, NH4F: ammonium fluoride, HF: 
hydrofluoric acid, H2SO4: sulfuric acid, NH4: ammonium, HCFC-141b: 1,1-Dichloro-1-fluoroethane, TCE: trichloroethylene, KOH: potassium hy-
droxide, H2SO4: sulfuric acid, H2O2: hydrogen peroxide, IPA: isopropyl alcohol, K2SO4: potassium sulfate, K2PO4: potassium phosphate, CH3SO3H: 
methane sulfuric acid, HNO3: nitric acid. 
*There is anecdotal evidence that case No. 3 may have worked in PM and could have been exposed to TCE and other chemical exposures.
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FAB department cases in Plant A
Two female operators (Case No. 1 and 2) and one male engi-
neer (Case No. 3) had worked in Plant A. Plant A operated 
15 production lines, with each of them occupying one or two 
floors of the plant. Each line had 80-150 workers and some of 
the lines were located in separate buildings. The dimensions of 
each line were approximately 100 m length × 54 m width × 3 
m height and they were composed of more than 25 bays. Each 
bay occupied an area of 3 m length × 25 m width × 3 m height. 
Case No. 1 and 2 had worked on the same line (line 3), and the 
other (Case No. 3) worked on different lines (1 and 5). 
Case No. 1 worked in the diffusion process - in bays 1, 
22, and 24 of line 3 - for 14 months since October 2003. Her 
duty was loading and unloading the wafer carrier to the dif-
fusion instruments. All instruments were automated and the 
process was closed. She then moved to the cleaning part of the 
wet etching process in bay 3 of  line 3. She worked there for 
6 months while her leukemia was developing. She manually 
dipped wafer boxes into a cleaning bath containing hydrogen 
peroxide and buffered oxide etchant (BOE) solution (mixture of 
ammonium fluoride, hydrofluoric acid and surfactant) (Table 3). 
Case No. 2 worked in the deposition process (especially 
CVD), which was in bays 6 and 9 of line 3, since January 1995 
for 9 years and 5 months. In this process, her duty was loading 
and unloading the wafer carrier to the Sputter procedure (Table 
3). All instruments were automated and the process was closed. 
She then worked in the labeling part of  line 3 for 9 months. 
Next, she worked in wet etching, the same location as Case 
No. 1 (bay 3 of line 3) for 5 months and diffusing (bay 22 of 
line 3) for 7 months. After that, she took a 3-month maternity 
leave. She came back to wet etching after delivery and worked 
for 1 month until her leukemia was diagnosed. Her duties in 
diffusion and wet etching were the same as those of Case No. 1. 
Although diffusion and deposition were automated and closed 
systems, she may have been exposed to other chemicals, espe-
cially when equipment was opened for loading and unloading. 
Case No. 3, a male FAB engineer, started his work in the 
chemical mechanical polishing (CMP) process in bay 5 of line 
5 for 4 years and 9 months on November 1997 (Table 3). He 
maintained instruments in FAB processes for 6 hours a day 
and did paper work for the remaining 2 hours of his shift. The 
main chemicals used for maintenance were ammonia and IPA. 
He changed slurry (composed of silica and ammonia), which 
was a polishing material used in the CMP process. In 2002, he 
was involved in setting up a new process line. According to his 
family, he sometimes participated in cleaning facilities, known 
as process maintenance (PM) tasks when mechanical errors oc-
curred, using several acids and solvents. However, a company 
manager denied this because all PM tasks had been outsourced 
to contractor engineers since 1995. Then he moved to the back-
lap part, which was in line 1, and worked there until March 
2005. The back-lap procedure involves grinding the wafer. 
His task was the same as the previous procedure. His family 
claimed that accidental high exposure to various chemicals oc-
curred during passing through vessels of  instruments during 
maintenance in the basement floor of the FAB process. Howev-
er, the employer asserted that there was no accident. We inter-
viewed coworkers who had worked with case 3. The coworkers 
agreed that the working environment and personal protective 
equipment were worse than the present equipment, and they 
used to use small amounts of trichloroethylene (TCE), which 
was unusual. Therefore, it seemed that if  he had performed the 
PM task, he might have been exposed to remnants of various 
chemicals in the baths and tanks.
In summary, based on available company records, the 
main chemical exposure was contents of the BOE solution or 
hydrogen peroxide during manual dipping in the cleaning part 
of the wet etching process for Case No. 1 and 2, and silica, am-
monia, and IPA for Case No. 3. Possible exposure to various 
secondary products generated from chemical reactions among 
UV-light, strong acids and bases, and several other chemicals 
may have also occurred. Because the FAB process was con-
ducted in a closed system, called the CLEAN ROOM, the air 
was re-circulated in the whole line, which meant that all pro-
cesses in the line might have similar exposure levels to certain 
chemicals generated from the instruments in the line. Another 
possible exposure was ionizing radiation, which was gener-
ated from an ion accelerating device during the ion implant 
process. The ion-accelerating device in this company was of a 
completely shielded type, which does not require permission 
to use. Devices generating radiation of less than 10 uSv/hr can 
be used just after reporting to a relevant agency, according to 
the notice of the Korean Ministry of Education, Science and 
Technology. The devices were located at both ends of the line 3 
floor, which was more than 10 m from the bay where Case No. 
1 and 2 worked. Because operators might pass through the aisle 
near the ion implanter while moving products, Case No. 1 and 
2 might have been exposed to radiation from them. Because 
the CMP process where Case No. 3 had worked was separated 
from the ionizing radiation generating facilities, there was no 
possibility of exposure to ionizing radiation. 
AS department cases in Plant B
Case No. 4 and 7 were female workers who had worked in 
the testing part of Plant B, where the electrical testing process 
is conducted. Case No. 4 started her duties in the FRONT 
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procedure where wafers were ground and sliced, and the wire 
was bonded. She tested tensile strength and performed micro-
scopic inspections. After 10 months, she was also involved in 
other procedures, such as quality control of MOLD, TIN and 
Trim/Form, PVI (package visual inspection), and TEST. In the 
MOLD and TIN procedures, she operated X-ray-generating de-
vices, an ultrasound instrument, and a laser measurement tool. 
She handled three X-ray-generating instruments (50 kVp/1.5 
mA - 100 kVp, 0.1 mA).
In the TIN procedure, she tested the reliability of the plat-
ing state using 1,1-dichloro-1-fluoroethane (HCFC-141b) and 
a solder bar (composed of tin, bismuth, and lead). The plating 
reliability test was conducted in a local vacuum system. The 
PVI task involved visual inspection of package exteriors, while 
TEST was the final visual inspection of the product. Case No. 
7 worked in the Monitoring Burn-In Test (MBT) procedure 
for 16 months, where chips were subjected to various voltages 
and temperatures to determine their long-term quality and reli-
ability, and to eliminate weak chips. The procedure involved 
insertion and removal of the chip to the sorter and test board 
and then heating it in a chamber to 125 degrees Celsius. She 
loaded and unloaded chips to the sorter, monitored them on a 
computer screen, and visually inspected the products.
Case No. 5 worked in the TRIM/FORM procedure for 
5 years from 1991 to 1996. In Trim & Form, lead frames were 
loaded into trim-and-form machines where lead fingers were 
formed step-by-step until finally the chips were severed from the 
frames. She loaded and unloaded products to the instrument, 
operated machinery, and moved products. Sometimes, she did 
visual inspections of products and cleaned molds with an air 
gun. Until 1995, TCE was used as a solvent to remove dusts 
from products. Thus, Case No. 5 could have been exposed to 
TCE during this period. Nine years after leaving the company, 
she was diagnosed with leukemia. 
Case No. 6, a male engineer in the AS plant, worked in 
the plating procedure for 5 years and 7 months. In the plating 
procedure, tasks of the engineer included maintenance of the 
facility and exchanging machine parts. He also cleaned and 
prepared the facility, called “Make-Up”, which involved the 
use of  water and putting plating chemicals in baths or tanks. 
These duties were conducted manually until 2000. During this 
process, he might have been exposed to several chemicals used 
for plating (Table 3). Ten years after leaving the company, he 
was diagnosed with non-Hodgkin’s lymphoma.
In summary, based on available company records, the 
main exposures of the test worker (Case No. 4) were HCFC-
141b, metals such as tin, bismuth, and lead, and ionizing radia-
tion. This is in contrast to the other test worker (Case No. 7) 
who might not have been exposed to chemicals. However, Case 
No. 7 might have been exposed to volatile organic chemicals 
(VOCs) during heating because products in the test procedure 
had undergone several chemical treatments, which could gen-
erate VOCs during the heating procedure. Case No. 5 also did 
not use many chemicals except for TCE, and Case No. 6 could 
have been exposed to various acids and bases with metals used 
in plating.
Measurement of carcinogenic factors 
Among the agents listed as being used by the seven cases (Table 
3), the only confirmed risk factor for LHP cancer was ionizing 
radiation. Ionizing radiation was measured using an ion cham-
ber for Case No. 1 and 2 who had possibly been exposed to 
ionizing radiation indirectly, if  any, and Case No. 4 who had 
handled X-ray-generating devices. The measuring points for 
Case No. 1 and 2 were located alongside their routine pathways 
during work because they were not operators for ion implants. 
Measuring points for Case No. 4 were placed in the X-ray 
room. The Korean Occupational Exposure Limit of  ionizing 
radiation is 50 mSv/year.
For Case No. 1 and 2, the dose levels of 8 of the 9 points 
were 0.20-0.22 uSv/hr, which were similar with the back-
ground level (0.21 μSv/hr) measured in the rest room of the 
same floor. One point was 2.4 uSv/hr. All five points measured 
for Case 4 were 0.54-0.58 nC/hr, which were lower than the 
background level (0.59 nC/hr) measured in the workers’ rest 
room of the same flour. 
Although carcinogenic chemicals related to LHP were not 
used in all seven cases’ processes, considering the possibility of 
generation from chemical reactions among the several agents 
used, airborne monitoring was conducted from June 2007 to 
May 2010, focusing on carcinogens related to LHP, such as 
benzene, and chemicals having hematologic effects. Benzene 
was measured for all processes, in which the seven cases were 
involved, and arsine, cellosolve, and ethylene glycols were 
measured for FAB workers. All the results of benzene, arsine, 
cellosolve, and ethylene glycols were lower than the minimum 
detection levels (3 ppb, 0.02 ppb, and 0.02 ppb, respectively). 
The detailed methods and results of  these measurements for 
Case No. 1 and 2 in the FAB department conducted in 2008 
were described in another paper [9]. In 2009, a following study 
was conducted to detect air benzene levels in three major FAB 
semiconductor companies, including the company where the 
cases occurred. The maximum concentration of  benzene de-
tected was 0.31 ppb (minimum detection level: 0.1 ppb) [10].
There were other records regarding chemical exposure in 
the company. By the Enforcement Regulation of the Occupa-
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Table 4. Results of airborne measurement of chemicals (2002-2007)
Chemicals OEL
Plant A Plant B
GM (range)
Frequency (%)
GM (range)
Frequency (%)
ND 10% <* 10-50%† ND 10% < 10-50%
Gases Cl2 0.5   0.004 (0.000-0.223)   59 (26) 169 (74)   1 (0.4)
O3 0.08 0.0004 (0.0000-0.0395)     5 (9)   50 (86)   3 (5)
CO2 5,000      583 (378-761)     0 (0)     4 (25) 12 (75)
NO 25 0.0002 (0.00-0.0101)   12 (26)   34 (74)   0
AsH3 5     0.02 (0.01-0.10)   52 (71)   21 (29)   0
PH3 0.3   0.001 (0.000-0.036)   56 (25) 163 (74)   2 (1)
CO 30     0.92 (0.40-1.50)     2 (3)   77 (97)   0
HCl 0.5   0.003 (0.000-0.056)   93 (22) 337 (78)   0     0.03 (0.00-0.08)   2 (18)   9 (82) 0 
Acid- 
  Bases
NH3 18     0.03 (0.00-0.27) 115 (23) 387 (77)   0
H2O2 1.5     0.01 (0.00-0.40)   33 (8) 330 (81) 46 (11) 
HF 0.5     0.01 (0.00-0.04) 262 (76)   83 (24)   0
HBr 2‡     0.02 (0.00-0.36) 134 (95)     7 (5)   0
KOH 2‡   0.003 (0.001-0.013)     2 (18)     9 (82)   0
H3PO4 1   0.005 (0.001-0.139)   33 (42)   44 (56)   2 (2)
HNO3 5   0.003 (0.00-0.066)   68 (22) 235 (78)   0
AA 25   0.101 (0.006-2.150)   42 (64)   24 (36)   0
H2SO4 0.2     0.01 (0.00-0.14) 107 (31) 234 (68)   3 (1)
Alcohols 
  & 
  Glycols
Methanol 200       0.5 (0.3-1.0)     2 (18)     9 (82)   0
Acetone 750       0.2 (0.0-4.1)     1 (5)   17 (95)   0       0.9 (0.2-4.5)   9 (82)   2 (18) 0
IPA 400       0.3 (0-9.9)   39 (8) 481 (92)   0     0.02 (0.00-0.35) 19 (80)   5 (20) 0
EG 50   0.001 (0.000-0.027)   60 (63)   35 (37)   0
Metals Cu 0.1 0.0002 (0.0001-0.0004) 10 (77)   3 (23) 0
Pb 0.05 0.0003 (0.0000-0.0013)   9 (39) 14 (61) 0
Sn 2   0.003 (0.0001-0.0176)   9 (69)   4 (31) 0
Others HCFC-141b 500     0.60 (0.08-1.63) 11 (69)   5 (31) 0
All the chemicals were measured during 8 working hour for a full time shift. 
Unit: parts per million (PPM) for gases except AsH3, alcohols and glycols and hydrofluoric acid, parts per billion (PPB) for AsH3, mg/m
3 for and 
metals and acid-bases except hydrofluoric acid, OEL: occupational exposure limit of Korea for 8 hour working time.
GM: geometric mean, ND: non-detectable, Cl2: chloride, O3: ozone, CO2: carbon dioxide, NO: nitrogen monoxide, AsH3: Arsin, PH3: phosphine, 
CO: carbon monoxide, NH3: ammonia, HCL: Hydrochloric acid, H2O2: hydrogen peroxide, HF: hydrofluoric acid, HBr: hydrobromic acid, H2SO4: 
sulfuric acid (Group 1 carcinogen in International Agency of Research on Cancer), HNO3: nitric acid, KOH: Potassium hydroxide, H3PO4: phos-
phoric acid, AA: acetic acid, IPA: isopropyl alcohol, EG: ethylene glycol, Cu: copper, Pb: lead, Sn: Tin. 
*Lower than 10% of OEL. 
†10-50% of OEL. 
‡Ceiling limit.
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tional Safety and Health Act [11], employers should perform 
airborne measurements for 190 chemicals and physical agents 
at worksites. The major results of  airborne measurement for 
the seven cases’ processes from 2002 to 2007 are summarized 
in table 4. There were eight gases, three metals, nine acid-bases, 
four alcohols, eight glycols, and a chlorofluorocarbon com-
pound measured at the worksites, and the values were based on 
the 8-hour time weighted average. Most of the chemicals were 
measured at levels below 10 % of the Korean Occupational Ex-
posure Limit (OEL) [11] (Table 4). Some of the higher values 
of gases (ozone, chloride, carbon dioxide, chloride, and phos-
phine), acids, and bases (hydrogen peroxide, phosphoric acid, 
and sulfuric acid) were 10-50 % of  the OEL (Table 4). The 
measurement records before 2002 were not available because 
of a lack of information.
For general features of  chemical hazards in the Korean 
semiconductor industry, material safety data sheets (MSDS) 
from 9 plants of 6 major semiconductor companies including 
the cases’ company were reviewed in 2008. As a result, 263 
different chemicals were compiled. Among them, 18 agents 
were group 1 and 2 carcinogens, classified by the International 
Agency of  Research on Cancer (IARC), of  which 5 agents 
(ethylene oxide, formaldehyde, ionizing radiation, perchloro-
ethylene, and trichloroethylene) were correlated with leukemia 
or NHL (Table 5). Among 263 chemicals, ethylene oxide and 
formaldehyde were not found in the cases’ company. However, 
ethylene oxide was found in one chemical at a level of 0.001% 
in another company and formaldehyde was found in a resin at 
a level of 0.1% in an ink in another company. Ionizing radia-
tion was detected in the process conducted by Case No. 1, 2, 
and 4, even though the dose was at a background level. Case 
No. 3 and Case No. 5 may have been exposed to TCE from 
1991 through 1995. Perchloroethylene was detected in only one 
sample, of which the level was 0.003 ppm at Plant A. 
Table 5. Carcinogens with some chemicals having hematologic effects using in plant A and B
Category Chemicals Effects Process
Group 1 Lead chromate Lung cancer Utility 
Arsenic compounds Lung cancer Ion implant from arsine
Ethylene oxide Lymphohematogenous cancer Etching
Sulfuric acid Lung and laryngeal cancer Cleaning of etching and assembly, deposition, utility
Silicon dioxide Lung cancer Deposition
Nickel Lung and nasal cavity cancer Diffusion, deposition
Formaldehyde Nasal cavity, Pharyngeal cancer, leukemia Assembly
Ionizing radiation Bone, lung, liver, thyroid cancer, leukemia and 
other sites
Ion implant, testing in assembly
Group 2A Tetrachloroethylene Cervix, esophagus, non-Hodgkin lymphoma Cleaning and lithography in FAB
Trichloroethylene Liver & biliary tract, cervix, non-Hodgkin lymphoma Cleaning of trim/form in assembly
Ultraviolet radiation Melanoma Lithography in FAB
Group 2B Lead compounds, 
inorganic
Lung Etching, ion implant, deposition, analytic lab form FAB
Plating, QE lab, trim/form, mold, soldering from as-
sembly
Carbon black Lung cancer Utility
Antimony trioxide Lung cancer Ion implant form FAB, assembly
Catechol Skin cancer Cleaning of etching form FAB
Dioxane Nasal cavity liver and skin Etching from FAB
Ethylbenzene Lung, Liver, Kidney Lithography from FAB
Naphthalene Respiratory Etching from FAB
FAB: fabrication, QE: quality engineering.
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Discussion
Several confirmed human carcinogenic agents for occupational 
LHP cancer have been identified by IARC (Group 1), including 
benzene, ionizing radiation, ethylene oxide, 1,3-butadiene, and 
formaldehyde [12]. Among the chemicals used as raw materials 
and additives in the company where the seven cases occurred, 
none were IARC Group 1 human carcinogenic chemicals for 
LHP cancers (Table 2). The MSDSs for ethylene oxide and 
formaldehyde were found at some other major semiconductor 
companies, although their use has been very limited, but not 
from Plants A and B (Table 5).
It was suspected that various kinds of chemicals, includ-
ing carcinogens, have been used in the semiconductor industry 
[2,13]. However, the detailed figures of chemicals and their car-
cinogenic risk in the industry have been veiled because of trade 
secrets in the high technology industry. In 2010, HSE found 
seven kinds of group 1 and 2 carcinogens designated by IARC 
(antimony trioxide, arsenic compounds, carbon tetrachloride, 
ceramic fiber, chromium, sulfuric acid, and trichloroethylene) 
[5], but none of them were LHP cancer-related. In 2007, the 
National Institute for Occupational Safety and Health in the 
US (NIOSH) reported the chemicals list used in an IBM plant 
(Endicotte) [14]. The report listed 20 known human carcino-
gens (IARC group 1) among 198 chemicals used from the late 
1970s to 2004. Of these 20 carcinogens, benzene and formalde-
hyde were known human carcinogens with strong associations 
with LHP. However HSE and NIOSH did not measure air lev-
els in the companies at that time. 
To the best of our knowledge, air measurements of carci-
nogenic agents related with LHP cancer in the semiconductor 
industry have not been previously reported. During 2007 to 
2010, OSHRI measured air benzene levels at the workplace of 
the seven cases, but benzene was not detected from all samples 
[9]. The maximum benzene level from another study conducted 
in 2009 [10] was 0.31 ppb (minimum detection level: 0.1 ppb), 
which did not differ from the outside air concentration (less 
than 0.30 ppb) measured at the same time. Because most ma-
jor chemicals used in the FAB department are passed through 
closed vessels in the automated system, exposure levels of most 
chemicals are low during normal procedures. The chemical lev-
els from the annual work environment measurements required 
by the law (Table 4) were also low. Low concentration chemical 
exposure has also been reported in other studies. The most fre-
Table 6. Review of exposure level of chemicals in semiconductor processes
Ref. No. Process Chemicals Airborne exposure level
[15] Coating of copper 
laminate circuit 
2-Methoxyethanol 3.31 (0.57-15.64) ppm
[17] Maintenance of 
wafer fabrication
Arsenic Normal operating in implantation: 6 mug /m3
Engineers in maintenance works: 7.7 mug /m3
Inside an ion implantation chamber; 218.6 mug /m3
[18,19] Wafer fabrication Gallium Operator: 12.25 (0.34-101.26) ug/m3    Engineer: 10.72 (0.25-100.27) ug/m3
Indium Operator: 8.43 (0.14-100.62) ug/m3      Engineer: 7.83 (0.25-99.23) ug/m3
Arsenic Operator: 25.66 (5.26-106.12) ug/m3    Engineer: 22.42 (4.71-102.35) ug/m3
[20] Implantation Arsenic, Boron, Phosphorous Below OSHA PEL (0.01, mg/m3, 15 mg/m3, 0.1 mg/m3)
Ionizing radiation Below OSHA PEL (1.25 rems per calendar quarter)
[16] Etching Fluorides 0.001 (< 0.0001-0.03) mg/m3 
Photolithography 2-Ethoxyethyl acetate 0.124 (< 0.001-4.00) mg/m3
1-Methoxy-2-propyl acetate 0.047 (< 0.001-0.25) mg/m3
n-Butyl acetate 0.067 (< 0.001-0.99) mg/m3
Xylene 0.153 (< 0.001-1.99) mg/m3
Acetone 0.008-17.3
Isopropanol 0.025-6.98
OSHA: Occupational Safety and Health Administration in United States, PEL: permissible exposure limit.
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quently studied chemicals in the semiconductor industry were 
[15,16], halides [16], highly toxic gases such as arsine [17], and 
rare-earth metals [18,19] such as gallium, indium, and arsenic 
(Table 6). The concentration of gases, metals, glycols, and other 
organic solvents from FAB industries [16-19] were low.
The exact level of exposures before 2002 at this company 
remains unknown, because the details of  the cases’ previous 
working environments are unavailable at present. However, 
considering the working process and measurement results, we 
cannot conclude that the concentration of  chemicals, includ-
ing carcinogens related to LHP cancer, in previous workplaces 
might be much higher than the current level.
For benzene, the risk of  LHP cancer has been reported 
to double from 40 ppm-years of cumulative doses of benzene 
[20]. Compared to this level, exposure duration of  the seven 
cases was not enough to develop LHP cancer, especially at this 
low level of exposure. One study reported that even under low 
levels of exposure, exposure durations longer than 20 years [21], 
or very high levels of peak exposure (higher than 100 ppm) [22], 
might increase the risk of LHP cancers. However, the exposure 
periods of all cases in this study were less than 20 years (6 of 
them were < 10 years) (Table 1), and the peak exposure level 
was far below 100 ppm. There was no known benzene in major 
raw materials and ingredients in the semiconductor industry. 
We can assume that benzene could be generated from chemical 
interaction of other chemicals, however, this may result in very 
low levels. Therefore, accidental high levels of exposure to ben-
zene is very unlikely. In addition, two cases (Case No. 1 and 7) 
had exposure durations of less than two years, and LHP cancer 
developed 9 to 10 years after leaving the company in two other 
cases (Case No. 5 and 6).
Two cases were presumed to be exposed to ion implan-
tation instrument radiation for 20 months and 11 years, re-
spectively; however, these instruments were located far from 
their working areas. Another case operated X-ray-generating 
instruments for 33 months. All three cases were diagnosed with 
AML, which is compatible with radiation-related cancer. How-
ever, all ionizing radiation measurements for these cases were 
similar to background levels except one measurement point 
for 5 samples (2.4 uSv/hr). Under normal working conditions, 
radiation exposure may not be regarded as a risk in the semi-
conductor industry; consequently, exposure levels have rarely 
been studied until now. One study reporting on ionizing radia-
tion using personal badge dosimetry in an ion implant process 
[19], and it showed levels less than the Permissible Exposure 
Limit (PEL) of  Occupational Safety and Health Administra-
tion (OSHA) in the US, which is 1.25 rem per calendar quarter 
for whole body radiation. In 2009, another study on the ion-
izing radiation exposure in the semiconductor industry was 
conducted by OSHRI. In this study, the ionizing radiation level 
was 0.15 ± 6.49 (0.01-13.32) uSv/hr.
Therefore, this information indicated that serious expo-
sures are unlikely to occur while engineering controls remain 
intact. Because the ion implant and X-ray-generating instru-
ments operated by Case No. 1, 2, and 5 had safety guards to 
prevent accidental exposure during operation and did not oper-
ate when the safety guards were released, there was no acciden-
tal exposure to radiation according to company records. Some 
of  the co-workers claimed there might have been accidental 
radiation exposure because they had been told that some of 
the previous workers used to open the ion implant operation to 
speed up operation. If  this happened, the workers would be ex-
posed to high doses of radiation over short periods. However, 
after reviewing the cases’ medical records we found no evi-
dence of any acute health effects, such as radiation dermatitis, 
which would result from acute exposure to high doses of radia-
tion.
Although LHP cancer is one of the most important occu-
pational cancers, increased risk in the semiconductor industry 
is inconclusive. Major studies on standardized mortality ratios 
(SMR) or standardized rate ratios of cancers in semiconductor 
workers have been conducted in the UK [4,5,23-25] and the 
US [1,26,27]. The cancer risks found in these studies were not 
consistent. The facilities studied by HSE in the UK were the 
NSUK [4,5] and West midlands semiconductor factory [23-
25]. Increased risk was found in the LHP, buccal cavity, and 
skin from West midlands factory workers, and in the central 
nervous system, oral cavity, stomach, and lung from the NSUK 
study. However, none of  them were statistically significant. 
Facilities in the US were located in East Fishkill, New York, 
and San Jose, California [1,26,27]. East Fishkill and San Jose 
showed increased risks in various sites (colorectum, pancreas, 
skin, breast, prostate, kidney, NHL, and multiple myeloma); 
however, none of them were statistically significant except for 
prostate cancer. In contrast, a 2005 Taiwanese study reported a 
statistically significant increase of leukemia (SMR 3.3, 1.1-7.8) 
in 5 male cases [28], however, no detailed articles have been 
reported in peer-reviewed journals to date. 
The differences according to country and factory may be 
due to the difference of the main product and its processes, and 
the operation period of each factory. The main process of East 
Fishkill, NSUK, and West midlands was wafer fabrication, 
and San Jose was storage devices. NSUK and West midlands 
had been operating since the 1970s, but East Fishkill and San 
Jose began earlier (1963 and 1956, respectively). Therefore, at 
this moment, estimations of cancer risk in semiconductor in-
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dustries have been inconsistent, and no specific cancer sites for 
increased risk have been indicated. 
The Epidemiological Investigation Review Board, which 
is one of the committees that issues scientific opinions on work-
relatedness for claimed cases to COMWEL, concluded that 
the evidence of a causal relationship between malignant LHP 
disorder and the semiconductor industry is insufficient. The 
Board recommended that retrospective cohort studies which 
were conducted in 2008 by OSHRI should be continued until 
enough person-years have been accumulated in the cohort, in 
order to determine more consistent and scientific conclusions. 
The major limitation of this study is the lack of exposure 
information before 2002 and many of  the cases had started 
to work before 2002. Especially, Case No. 2, 3, 5, and 6 had 
begun to work in 1990s, for which we could not obtain exact 
information of exposure, such as to TCE or other chemicals at 
the time. Although we assume that the exposure level of car-
cinogenic agents related to LHP cancers, such as benzene and 
radiation, were not high based on the exposure assessments 
which OSHRI conducted in 2008 [9] and 2009 [10], it is impos-
sible to confirm this assumption regarding the detailed situa-
tions of the exposures. 
The association between benzene and leukemia was first 
announced in 1974 [29] and confirmed in 1982 [30]. Since 
then, ionizing radiation was confirmed as having a strong as-
sociation with leukemia [31]. In 2008, ethylene oxide and1,3-
butadiene were found to have a strong link with LHP cancer 
[32]. And most recently (2009), the IARC concluded that 
formaldehyde was strongly correlated with leukemia [33]. To 
seek out more scientific facts on occupational cancers in the 
semiconductor industries, devoted research with international 
collaboration is essential. Long enough follow up of the cohort 
study including workers of  contractors would be necessary 
for drawing scientific conclusion about causal-relationship for 
LHP disorders in the semiconductor industry. 
In conclusion, from this investigation, we could not find 
sufficient evidence of  exposure to occupational carcinogens 
in all seven cases. Known carcinogens related to LHP cancers 
were not found. Some carcinogenic chemicals like benzene 
were measured and were determined to be at background levels 
when the sensitivity of  detection levels were increased. The 
risk of LHP cancer seems to be very low, when we consider the 
possible exposure level to carcinogenic agents such as benzene, 
formaldehyde, ethylene-oxide, and ionizing radiation, although 
detailed information for exposure levels before 2002 was not 
available.
Although, we could not find convincing evidence on 
known carcinogens for LHP cancers, and the epidemiological 
studies on that were inconclusive, we do not know the possibil-
ity of an unknown cause of LHP cancer or effects of multiple 
exposures of several chemicals in the semiconductor industry. 
Therefore, long-term future studies are needed to confirm the 
current result. 
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